Get a Free Consultation
Non-Small Cell Lung Cancer MET Clinical Trials

Non-Small Cell Lung Cancer MET Clinical Trials

Non-Small Cell Lung Cancer MET Clinical Trials help to advance treatments for patients for the future by finding better alternatives to standard therapies, often with less side effects. MET alterations are most common in lung cancer, but they also occur in several other cancer types. In some cases of lung cancer, specifically non-small cell lung cancer, the MET gene amplification can cause cancerous cells to reproduce and spread more aggressively than lung cancer cases without known biomarkers. Patients that test positive for a MET amplification may respond better to a MET targeted therapy, than standard treatments. Fill out the form on this page to download the full newsletter.

MET Crusaders Cancer Patient and Caregiver Support Group created the Q3 2021 Research Edition of the Crusader Newsletter including a review of the latest therapies and clinical trials for lung cancer and MET alterations. The newsletter evaluates clinical trial therapies and topics such as:

  • Telisotuzumab vedotin
  • Impact of oncogene mutations on tumor mutational burden (TMB)
  • PD-L1 expression in NSCLC
  • Frequency of actionable molecular drivers in NSCLC
  • Real-world insights into patients with NSCLC and MET Alterations
  • Characterization of NSCLC With MET Exon 14 Skipping Alterations
  • Osimeritinib, crizotinib
  • Correlation between PD-L1 expression and MET gene amplification in NSCLC
  • Selpercatinib, capmatinib

MET Crusaders Cancer Patient and Caregiver Support Group was founded in 2019 by MET lung cancer survivor John Hallick, when he was seeking ways to help others with MET altered cancer and wanted to promote new treatments. Today, MET Crusaders is a community dedicated to helping lung cancer patients with MET alterations live normal lives. You can download and read the full Crusader Newsletter below.

Download the Crusader Newsletter

MET Alteration Clinical Trials

Non-small cell lung cancer MET alteration clinical trials have shown improved outcomes with targeted therapy and immunotherapy drugs. There are over 60 lung cancer MET-amplified clinical trials available to eligible patients. Fill out the form to download and read the full newsletter for more on clinical trials and therapies targeting MET alterations in lung cancer. There is also more information about these trials and lung cancer with MET alterations on the MET Crusaders website and Facebook group

Leave a Reply

Your email address will not be published. Required fields are marked *

Join our community
and receive our newsletter